Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: Update and report from a pharmacogenetic service clinic

International Review of Psychiatry

Volumn 25, Issue 5, 2013, Pages 554-571

  Müller, Daniel J ^a   Kekin, Ivana ^b   Kao, Amy C C ^a   Brandl, Eva J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ALIMEMAZINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PIMOZIDE; PROLACTIN; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ALLELE; ANXIETY DISORDER; ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; HEART ARRHYTHMIA; HUMAN; MENTAL HEALTH; MOOD DISORDER; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TIC; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; HUMANS; PHARMACOGENETICS; PSYCHOTROPIC DRUGS;

EID: 84886653435     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2013.838944     Document Type: Article

References (90)

1. Adli, M., Bauer, M. & Rush, A.J. (2006). Algorithms and collaborative-care systems for depression: Are they effective and why? A systematic review. Biological Psychiatry, 59, 1029-1038.
2. Alenius, M., Wadelius, M., Dahl, M.L., Hartvig, P., Lindstrom, L. & Hammarlund-Udenaes, M. (2008). Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of Psychiatric Research, 42, 884-893.
3. Anderson, I.M., Nutt, D.J. & Deakin, J.F. (2000). Evidencebased guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psycho pharmacology guidelines. British Association for Psychopharmacology. Journal of Psycopharmacology, 14, 3-20.
4. Azuma, J., Hasunuma, T., Kubo, M., Miyatake, M., Koue, T., Higashi, K.,. Hara, S. (2012). The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. European Journal of Clinical Pharmacology, 68, 29-37.
5. Barbui, C., Esposito, E. & Cipriani, A. (2009). Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies. Canadian Medical Association Journal, 180, 291-297.
6. Bartecek, R., Jurica, J., Zrustova, J., Kasparek, T., Pindurova, E. & Zourkova, A. (2012). Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuro Endocrinology Letters, 33, 236-244.
7. Berwaerts, J., Cleton, A., Herben, V., van de Vliet, I., Chang, I., van Hoek, P. & Eerdekens, M. (2009). The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry, 42, 158-163.
8. Bigos, K.L., Bies, R.R., Pollock, B.G., Lowy, J.J., Zhang, F. & Weinberger, D.R. (2011). Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Molecular Psychiatry, 16, 620-625.
9. Bijl, M.J., Visser, L.E., Hofman, A., Vulto, A.G., van Gelder, T., Stricker, B.H. & van Schaik, R.H. (2008). Influence of the CYP2D6 * 4 polymorphism on dose, switching and discontinuation of antidepressants. British Journal of Clinical Pharmacology, 65, 558-564.
10. Bishop, J.R., Ellingrod, V.L., Akroush, M. & Moline, J. (2009). The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: Possible relationship to oral contraceptives. Human Psychopharmacology, 24, 207-215.
11. Bondolfi, G., Morel, F., Crettol, S., Rachid, F., Baumann, P. & Eap, C.B. (2005). Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Therapeutic Drug Monitoring, 27, 539-543.
12. Brandl, E.J., Tiwari, A.K., Zhou, X., Deluce, J., Kennedy, J.L., Mü ller, D.J. & Richter, M.A. (2013). Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics Journal. doi: 10.1038/tpj.2013.12
13. Brockm ö ller, J., Meineke, I. & Kirchheiner, J. (2007). Pharmacokinetics of mirtazapine: Enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clinical Pharmacology and Therapeutics, 81, 699-707.
14. Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., de Girolamo, G.,. Kessler, R.C. (2011). Cross-national epidemiology of DSM-IV major depressive episode. BMC Medicine, 9, 90.
15. Calarge, C.A. & Miller, D.D. (2011). Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21, 163-169.
16. Crescenti, A., Mas, S., Gasso, P., Parellada, E., Bernardo, M. & Lafuente, A. (2008). Cyp2d6 * 3, * 4, * 5 and * 6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clinical and Experimental Pharmacology and Physiology, 35, 807-811.
17. de Vos, A., van der Weide, J. & Loovers, H.M. (2011). Association between CYP2C19 * 17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics Journal, 11, 359-367.
18. Dorado, P., Pe ñ as-LLed ó, E.M., de la Rubia, A. & LLerena, A. (2009). Relevance of CYP2D6-1584C-G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics, 10, 1083-1089.
19. Dunbar, L., Miles, W., Wheeler, A., Sheridan, J., Pulford, J. & Butler, R. (2009). The CYP2D6 metaboliser status of patients prescribed risperidone for the treatment of psychosis. New Zealand Medical Journal, 122, 29-34.
20. Fleeman, N., Dundar, Y., Dickson, R., Jorgensen, A., Pushpakom, S., McLeod, C.,. Walley, T. (2011). Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: Systematic review and meta-analyses. Pharmacogenomics Journal, 11, 1-14.
21. Gex-Fabry, M., Eap, C.B., Oneda, B., Gervasoni, N., Aubry, J.M., Bondolfi, G. & Bertschy, G. (2008). CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Therapeutic Drug Monitoring, 30, 474-482.
22. Gonzalez-Tejera, G.M. & Corey, S. (2009). CYP2D6 genotypes in Puerto Rican psychiatry patients with intolerance of antidepressants and antipsychotics. Boletin de la Asociacion Medica de Puerto Rico, 101, 7-12.
23. Gunes, A., Spina, E., Dahl, M.L. & Scordo, M.G. (2008). ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Therapeutic Drug Monitoring, 30, 628-633.
24. Gvozdic, K., Brandl, E.J., Taylor, D.L. & M ü ller, D.J. (2012). Genetics and personalized medicine in antidepressant treatment . Current Pharmaceutical Design, 18, 5853-5878.
25. Hall-Flavin, D.K., Winner, J.G., Allen, J.D., Jordan, J.J., Nesheim, R.S., Snyder, K.A.,. Mrazek, D.A. (2012). Using a pharmacogenomic algorithm to guide the treatment of depression . Translational Psychiatry, 2, e172.
26. Hendset, M., Haslemo, T., Rudberg, I., Refsum, H. & Molden, E. (2006). The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry, 39, 121-127.
27. Hendset, M., Molden, E., Refsum, H. & Hermann, M. (2009). Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. Journal of Clinical Psychopharmacology , 29, 537-541.
28. Herbild, L., Bech, M., Gyrd-Hansen, D., Christensen, M., Werge, T. & Nielsen, K.A. (2011). Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services? Scandinavian journal of public health 39, 147-155.
29. Hicks, J.K., Swen, J.J., Thorn, C.F., Sangkuhl, K., Kharasch, E.D., Ellingrod, V.L.,. Stingl, J.C. (2013). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants . Clinical pharmacology and therapeutics, 93, 402-408.
30. Huezo-Diaz, P., Perroud, N., Spencer, E.P., Smith, R., Sim, S., Virding, S.,. Aitchison, K.J. (2012). CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. Journal of Psycopharmacology, 26, 398-407.
31. Ishak, K.J., Tan, Y., Glass, J., Luong, D. & Caro, J.J. (2008). Risk of discontinuation of risperidone after exposure to potentially interacting drugs: A nested case-control study in patients with schizophrenia. Clinical Therapeutics, 30, 1251-1263.
32. Jaquenoud Sirot, E., Knezevic, B., Morena, G.P., Harenberg, S., Oneda, B., Crettol, S.,. Eap, C.B. (2009). ABCB1 and cytochrome P450 polymorphisms: Clinical pharmaco genetics of clozapine. Journal of Clinical Psychopharmacology, 29, 319-326.
33. Jin, Y., Pollock, B.G., Frank, E., Cassano, G.B., Rucci, P., Mü ller, D.J.,. Bies, R.R. (2010). Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. Journal of Clinical Pharmacology, 50, 62-72.
34. Jovanovic, N., Bozina, N., Lovric, M., Medved, V., Jakovljevic, M. & Peles, A.M. (2010). The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidone. European Journal of Clinical Pharmacology, 66, 1109-1117.
35. J ü rgens, G., Rasmussen, H.B., Werge, T., Dalhoff, K., Nordentoft, M. & Andersen, S.E. (2012). Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum? Journal of Clinical Psychopharmacology , 32, 100-105.
36. Kang, R.H., Jung, S.M., Kim, K.A., Lee, D.K., Cho, H.K., Jung, B.J., Kim, Y.K., Kim, S.H., Han, C., Lee, M.S. & Park, J.Y. (2009). Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol, 29, 272-277.
37. Kandasamy, M., Srinivas, P., Subramaniam, K., Ravi, S., John, J., Shekar, R.,. Thangam, S. (2010). Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes-Focus on venlafaxine and O-desmethylvenlafaxine . European Journal of Clinical Pharmacology, 66, 879-887.
38. Kim, J.R., Seo, H.B., Cho, J.Y., Kang, D.H., Kim, Y.K., Bahk, W.M.,. Jang, I.J. (2008). Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. British Journal of Clinical Pharmacology, 66, 802-810.
39. Kobylecki, C.J., Jakobsen, K.D., Hansen, T., Jakobsen, I.V., Rasmussen, H.B. & Werge, T. (2009). CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: A retrospective matched case-control study. Neuropsychobiology, 59, 222-226.
40. Kohlrausch, F.B., Gama, C.S., Lobato, M.I., Belmonte-de-Abreu, P., Callegari-Jacques, S.M., Gesteira, A.,. Hutz, M.H. (2008). Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and Genomics, 18, 599-609.
41. Kwadijk-de Gijsel, S., Bijl, M.J., Visser, L.E., van Schaik, R.H., Hofman, A., Vulto, A.G.,. Stricker, B.H. (2009). Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants. British Journal of Clinical Pharmacology, 68, 221-225.
42. Lee, S.T., Ryu, S., Kim, S.R., Kim, M.J., Kim, S., Kim, J.W.,. Hong, K.S. (2012). Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. Journal of Clinical Psychopharmacology, 32, 441-448.
43. Lind, A.B., Reis, M., Bengtsson, F., Jonzier-Perey, M., Powell Golay, K., Ahlner, J.,. Dahl, M.L. (2009). Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clinical Pharmacokinetics, 48, 63-70.
44. Lobello, K.W., Preskorn, S.H., Guico-Pabia, C.J., Jiang, Q., Paul, J., Nichols, A.I.,. Ninan, P.T. (2010). Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: A secondary analysis of 4 studies in major depressive disorder. Journal of Clinical Psychiatry, 71, 1482-1487.
45. Locatelli, I., Kastelic, M., Koprivsek, J., Kores-Plesnicar, B., Mrhar, A., Dolzan, V. & Grabnar, I. (2010). A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. European Journal of Pharmaceutical Sciences, 41, 289-298.
46. Mannheimer, B., von Bahr, C., Pettersson, H. & Eliasson, E. (2008). Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Therapeutic Drug Monitoring, 30, 565-569.
47. Mas, S., Gasso, P., Alvarez, S., Parellada, E., Bernardo, M. & Lafuente, A. (2012). Intuitive pharmacogenetics: Spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics Journal, 12, 255-259.
48. McAlpine, D.E., Biernacka, J.M., Mrazek, D.A., O ' Kane, D.J., Stevens, S.R., Langman, L.J.,. Moyer, T.P. (2011). Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Therapeutic Drug Monitoring, 33, 14-20.
49. Mrazek, D.A. (2010). Psychiatric Pharmacogenomics. New York: Oxford University Press.
50. Mrazek, D.A., Biernacka, J.M., O ' Kane, D.J., Black, J.L., Cunningham, J.M., Drews, M.S.,. Weinshilboum, R.M. (2011). CYP2C19 variation and citalopram response. Pharmacogenetics and Genomics, 21, 1-9.
51. M ü ller, D.J., Brandl, E.J., Hwang, R., Tiwari, A.K., Sturgess, J.E., Zai, C.C.,. Richter, M.A. (2012). The AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic Testing and Molecular Biomarkers, 16, 897-903.
52. M ü ller, D.J., Chowdhury, N.I. & Zai, C.C. (2013). The pharmacogenetics of antipsychotic-induced adverse events. Current Opinion in Psychiatry, 26, 144-150.
53. Nagai, G., Mihara, K., Nakamura, A., Suzuki, T., Nemoto, K., Kagawa, S.,. Kondo, T. (2012). Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry and Clinical Neurosciences, 66, 518-524.
54. Nichols, A.I., Focht, K., Jiang, Q., Preskorn, S.H. & Kane, C.P. (2011). Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: A randomized, open-label, two-period, parallelgroup, crossover study. Clinical Drug Investigation, 31, 155-167.
55. Novalbos, J., Lopez-Rodriguez, R., Roman, M., Gallego-Sandin, S., Ochoa, D. & Abad-Santos, F. (2010). Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Journal of Clinical Psychopharmacology, 30, 504-511.
56. Nozawa, M., Ohnuma, T., Matsubara, Y., Sakai, Y., Hatano, T., Hanzawa, R.,. Arai, H. (2008). The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Therapeutic Drug Monitoring, 30, 35-40.
57. Parker, G., Rowe, M., Mehta, F. & Kumar, S. (2010). Will a new genotyping tesThelp the clinician predict response to antidepressant drugs? Australasian Psychiatry, 18, 413-416.
58. Penas-Lledo, E.M., Blasco-Fontecilla, H., Dorado, P., Vaquero-Lorenzo, C., Baca-Garcia, E. & Llerena, A. (2012). CYP2D6 and the severity of suicide attempts. Pharmacogenomics , 13, 179-184.
59. Peters, E.J., Slager, S.L., Kraft, J.B., Jenkins, G.D., Reinalda, M.S., McGrath, P.J. & Hamilton, S.P. (2008). Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR * D sample. PloS One, 3, e1872.
60. Plesnicar, B.K. (2010). Personalized antipsychotic treatment: The adverse effects perspectives. Psychiatria Danubina, 22, 329-334.
61. Porcelli, S., Fabbri, C., Spina, E., Serretti, A. & De Ronchi, D. (2011). Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opinion On Drug Metabolism and Toxicology, 7, 1101-1115.
62. Rogers, H.L., Bhattaram, A., Zineh, I., Gobburu, J., Mathis, M., Laughren, T.P. & Pacanowski, M. (2012). CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration ' s new dosing recommendations. Journal of Clinical Psychiatry, 73, 1187-1190.
63. Rudberg, I., Hermann, M., Refsum, H. & Molden, E. (2008a). Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. European Journal of Clinical Pharmacology, 64, 1181-1188.
64. Rudberg, I., Mohebi, B., Hermann, M., Refsum, H. & Molden, E. (2008b). Impact of the ultrarapid CYP2C19 * 17 allele on serum concentration of escitalopram in psychiatric patients. Clinical Pharmacology and Therapeutics, 83, 322-327.
65. Rundell, J.R., Staab, J.P., Shinozaki, G., Saad-Pendergrass, D., Moore, K., McAlpine, D. & Mrazek, D. (2011). Pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice. Psychosomatics, 52, 141-146.
66. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Stewart, J.W., Nierenberg, A.A., Thase, M.E.,. Fava, M. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine, 354, 1231-1242.
67. Schenk, P.W., van Fessem, M.A., Verploegh-Van Rij, S., Mathot, R.A., van Gelder, T., Vulto, A.G.,. van Schaik, R.H. (2008). Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Molecular Psychiatry, 13, 597-605.
68. Schenk, P.W., van Vliet, M., Mathot, R.A., van Gelder, T., Vulto, A.G., van Fessem, M.A.,. van Schaik, R.H. (2010). The CYP2C19 * 17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics Journal, 10, 219-225.
69. Serretti, A., Calati, R., Massat, I., Linotte, S., Kasper, S., Lecrubier, Y.,. Souery, D. (2009). Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. International Clinical Psychopharmacology, 24, 250-256.
70. Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L.X., Sibley, D.R.,. Mailman, R. (2003). Aripiprazole, anovel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28, 1400-1411.
71. Sim, S.C., Nordin, L., Andersson, T.M., Virding, S., Olsson, M., Pedersen, N.L. & Ingelman-Sundberg, M. (2010). Association between CYP2C19 polymorphism and depressive symptoms. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 153B, 1160-1166.
72. Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G. & Fuselli, S. (2007). CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenetics and Genomics, 17, 93-101.
73. Skogh, E., Sjodin, I., Josefsson, M. & Dahl, M.L. (2011). High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. Journal of Clinical Psychopharmacology, 31, 4-9.
74. Suzuki, T., Mihara, K., Nakamura, A., Nagai, G., Kagawa, S., Nemoto, K.,. Kondo, T. (2011). Effects of the CYP2D6 * 10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic Drug Monitoring, 33, 21-24.
75. Suzuki, Y., Fukui, N., Tsuneyama, N., Watanabe, J., Ono, S., Sugai, T.,. Someya, T. (2012). Effect of the cytochrome P450 2D6 * 10 allele on risperidone metabolism in Japanese psychiatric patients. Human Psychopharmacology, 27, 43-46.
76. Suzuki, Y., Sugai, T., Fukui, N., Watanabe, J., Ono, S., Inoue, Y.,. Someya, T. (2011). CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. Journal of Psycopharmacology, 25, 908-914.
77. Swen, J.J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A.H., Mulder, H.,. Guchelaar, H.J. (2011). Pharmacogenetics: from bench to byte-An update of guidelines . Clinical Pharmacology and Therapeutics, 89, 662-673.
78. Timmer, C.J., Sitsen, J.M. & Delbressine, L.P. (2000). Clinical pharmacokinetics of mirtazapine. Clinical Pharmacokinetics 38, 461-474.
79. Tiwari, A.K., Souza, R.P. & M ü ller, D.J. (2009). Pharmacogenetics of anxiolytic drugs. Journal of Neural Transmission, 116, 667-677.
80. Tsai, M.H., Lin, K.M., Hsiao, M.C., Shen, W.W., Lu, M.L., Tang, H.S.,. Liu, Y.L. (2010). Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics , 11, 537-546.
81. Van Nieuwerburgh, F.C., Denys, D.A., Westenberg, H.G. & Deforce, D.L. (2009). Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. International Journal of Psychiatry in Clinical Practice, 13, 345-348.
82. Vetti, H.H., Molven, A., Eliassen, A.K. & Steen, V.M. (2010). Is pharmacogenetic CYP2D6 testing useful? Tidsskrift for den Norske Laegeforening, 130, 2224-2228.
83. Waade, R.B., Christensen, H., Rudberg, I., Refsum, H. & Hermann, M. (2009). Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Therapeutic Drug Monitoring, 31, 233-238.
84. Watanabe, J., Suzuki, Y., Fukui, N., Sugai, T., Ono, S., Inoue, Y. & Someya, T. (2008). Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Therapeutic Drug Monitoring, 30, 705-708.
85. Winner, J., Allen, J.D., Altar, C.A. & Spahic-Mihajlovic, A. (2013). Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Translational Psychiatry, 3, e242.
86. Xiang, Q., Zhao, X., Zhou, Y., Duan, J.L. & Cui, Y.M. (2010). Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. Journal of Clinical Pharmacology, 50, 659-666.
87. Yagihashi, T., Mizuno, M., Chino, B., Sato, Y., Sakuma, K., Takebayashi, T.,. Kosaki, K. (2009). Effects of the CYP2D6 * 10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Human Psychopharmacology, 24, 301-308.
88. Yoo, H.D., Cho, H.Y., Lee, S.N., Yoon, H. & Lee, Y.B. (2012). Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. J Pharmacokinet Pharmacodyn, 39, 329-341.
89. Zanger, U.M., Turpeinen, M., Klein, K. & Schwab, M. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry, 392, 1093-1108.
90. Zhou, S.F., Liu, J.P. & Chowbay, B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews, 41, 89-295.